Page last updated: 2024-11-13

gs-5816

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

velpatasvir: an NS5A inhibitor used for treating hepatitis C infections [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

velpatasvir : A complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID67683363
CHEMBL ID3545062
CHEBI ID133009
SCHEMBL ID8756902
SCHEMBL ID19236068
MeSH IDM000613523

Synonyms (61)

Synonym
CHEBI:133009
methyl {(2s)-1-[(2s,5s)-2-(9-{2-[(2s,4s)-1-{(2r)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1h-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-
gs 5816
gs-5816 ,
velpatasvir
gs5816
1377049-84-7
S3724
vosevi component velpatasvir
velpatasvir [orange book]
velpatasvir [usan]
epclusa component velpatasvir
velpatasvir component of epclusa
KCU0C7RS7Z ,
velpatasvir [jan]
velpatasvir [inn]
velpatasvir [mi]
velpatasvir component of vosevi
velpatasvir [who-dd]
unii-kcu0c7rs7z
velpatasvir [usan:inn]
methyl {(2s)-1-[(2s,5s)-2-(9-{2-[(2s,4s)-1-{(2r)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1h-imidazol-5-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-y
methyl{(2s)-1-[(2s,5s)-2-(9-{2-[(2s,4s)-1-{(2r)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1h-imidazol-5-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl
FHCUMDQMBHQXKK-CDIODLITSA-N
SCHEMBL8756902
AC-28744
CHEMBL3545062
HY-12530
DTXSID70722565
AKOS030525362
D10806
velpatasvir (jan/usan/inn)
methyl n-[(1r)-2-[(2s,4s)-2-(5-{6-[(2s,5s)-1-[(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.0?,??.0?,?.0??,??]henicosa-1,3,6,8,10,12,14,16,18-nonaen-17-yl}-1h-imidazol-2-yl)-4-(methoxymethyl)p
mfcd28411371
CS-5977
velpatasvir(gs5816)
DB11613
SCHEMBL19236068
methyl ((r)-2-((2s,4s)-2-(5-(2-((2s,5s)-1-((methoxycarbonyl)-l-valyl)-5-methylpyrrolidin-2-yl)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1h-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)carbamate
Z3064248323
FT-0700879
velpatasvir; gs-5816
EX-A2320
AS-35237
Q25018296
methyl n-[(1r)-2-[(2s,4s)-2-[5-[6-[(2s,5s)-1-[(2s)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-1(13),2,4(8),5,9,11,14(19),15,17-nonaen-17-yl]-1h-imidazol-2-yl]-4-(methoxy
gs-5816;gs5816;gs 5816
BCP13813
methyl [(2s)-1-[(2s,5s)-2-[9-[2-[(2s,4s)-1-[(2r)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1h-imidazol-5-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl]-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-y
AMY4211
CCG-270553
NCGC00522503-01
epclusa (sofosbuvir + velpatasvir)
gtpl11269
vosevi (sofosbuvir + velpatasvir + voxilaprevi)
A886410
NCGC00522503-02
bdbm50521720
METHYL N-[(1R)-2-[(2S,4S)-2-(5-{6-[(2S,5S)-1-[(2S)-2-[(METHOXYCARBONYL)AMINO]-3-METHYLBUTANOYL]-5-METHYLPYRROLIDIN-2-YL]-21-OXA-5,7-DIAZAPENTACYCLO[11.8.0.03,11.0?,?.01?,1?]HENICOSA-1,3,6,8,10,12,14,16,18-NONAEN-17-YL}-1H-IMIDAZOL-2-YL)-4-(METHOXYMETHYL)P
EN300-21607042
methyl n-[(1r)-2-[(2s,4s)-2-(5-{6-[(2s,5s)-1-[(2s)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-5-methylpyrrolidin-2-yl]-21-oxa-5,7-diazapentacyclo[11.8.0.0^{3,11}.0^{4,8}.0^{14,19}]henicosa-1(13),2,4(8),6,9,11,14(19),15,17-nonaen-17-yl}-1h-imidazol-2-yl)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" SOF-based therapy was well-tolerated, and no serious adverse events were reported."( Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Chen, B; Chen, EQ; Jiang, W; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB, 2019
)
0.51
" Efficacy was defined as HCV RNA below the lower limit of detection 12 weeks after the end of treatment (SVR12), while safety endpoints included the incidence of grade 3 and 4 adverse events (AEs) following treatment, and the proportion of patients who stopped treatment prematurely due to AEs."( A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E, 2019
)
0.51
"Retreatment with 12 weeks of SOF/VEL/VOX was safe and effective in patients with relapsed HCV following initial combination DAA-based treatment."( A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E, 2019
)
0.51
"Twelve weeks of the combination of direct-acting antivirals (SOF/VEL/VOX) was safe and effective in patients with relapsed hepatitis C virus infection who had previously received combination therapy with direct-acting antivirals."( A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E, 2019
)
0.51
" Adverse effects were mild and non-specific."( Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J, 2019
)
0.51
"Real-world data show that SOF/VEL/VOX is an effective, safe rescue therapy for patients with prior DAA treatment failure despite the presence of resistance-associated substitutions."( Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J, 2019
)
0.51
" Treatment with SOF/VEL/VOX is an effective and safe rescue therapy due to its high efficacy and very good safety profile."( Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J, 2019
)
0.51
" Plasma pharmacokinetic parameters were estimated by using noncompartmental models, and safety was assessed through clinical evaluation and monitoring of adverse events."( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020
)
0.56
" Secondary outcome was frequency of adverse events (AE)."( Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A, 2021
)
0.62
"Sofosbuvir plus Velpatasvir fixed-dose combination is safe and effective in treating CHC in patients with ESRD on MHD."( Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.
De, A; Dhiman, RK; Duseja, A; Kohli, HS; Kumar, V; Mehta, M; Premkumar, M; Ramachandran, R; Ratho, RK; Singh, MP; Singh, V; Taneja, S; Verma, N, 2021
)
0.62
" There were no adverse events related to the use of Sof-Vel, with no major fluctuations in cyclosporine levels."( Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation.
Bhakuni, P; Chakrabarti, S; Gupta, M; Jaiswal, SR; Soni, M; Thatai, A, 2021
)
0.62
"SOF-based pangenotypic DAAs including SOF plus DCV and SOF plus VEL, were effective and safe for CHC patients without GT determination in this study."( Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Chen, EQ; Chen, XB; Jiang, W; Li, J; Tao, YC; Wang, ML; Wang, YH; Wu, DB; Xiao, GB, 2020
)
0.56
" The secondary outcome measures were SVR12 stratified by the presence of decompensated cirrhosis, prior treatment, HCC, and HIV/hepatitis C virus coinfection and the occurrence rate of serious adverse events requiring treatment cessation or hospitalization."( Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ, 2021
)
0.62
" Apart from one patient who developed myositis, no other serious adverse events were observed."( Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ, 2021
)
0.62
"The SOF/VEL ± RBV is a safe and efficacious treatment option for GT3 HCV patients in a real-world setting."( Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ, 2021
)
0.62
" Adverse events were evaluated in all patients who started their assigned treatment."( Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.
Afsharian, M; Bozorgomid, A; Janbakhsh, A; Khodarahmi, R; Khosravi Shadmani, F; Mansouri, F; Miladi, R; Mohseni Afshar, Z; Najafi, F; Rahimi, Z; Salimi, M; Sayad, B; Shirvani, M; Vaziri, S; Zamanian, MH, 2021
)
0.62
"A 12 week course of sofosbuvir-velpatasvir-voxilaprevir is safe and efficacious for the re-treatment of individuals infected with HCV genotype 4 non-a/d subtypes with frequent baseline NS5A resistance-associated substitutions, following failure of previous direct-acting antiviral treatment."( Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Camus, G; Grant, PM; Gupta, N; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Mukabatsinda, C; Murangwa, A; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F, 2022
)
0.72
"A 12-week regimen of sofosbuvir-velpatasvir is safe and efficacious in treating chronic HCV genotype 4 infection in patients in Rwanda."( Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.
Camus, G; Grant, PM; Gupta, N; Kabakambira, JD; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Murangwa, A; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F; Sylvain, H, 2022
)
0.72
" Therefore, there is a need for effective and safe antiviral."( Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.
Adinolfi, LE; De Lucia Sposito, P; Fusco, R; Gaglione, P; Izzi, A; Lumino, P; Maggi, P; Marrone, A; Messina, V; Nevola, R; Rega, R; Rinaldi, L; Sasso, FC; Simeone, F, 2022
)
0.72
" Demographic information, HCV viral load (VL), profiles of lipid and sugar, and adverse events were recorded and reviewed."( Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD, 2022
)
0.72
" Serious adverse events (SAE) were registered."( Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
Diculescu, MM; Gheorghe, L; Iacob, SM; Iliescu, L; Istratescu, D; Manuc, M; Manuc, T; Popescu, CP; Preda, C; Stanciu, C; Stroie, TG; Tieranu, CG; Trifan, A, 2022
)
0.72
" Serious adverse events related to therapy were reported in 1/143(0."( Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
Diculescu, MM; Gheorghe, L; Iacob, SM; Iliescu, L; Istratescu, D; Manuc, M; Manuc, T; Popescu, CP; Preda, C; Stanciu, C; Stroie, TG; Tieranu, CG; Trifan, A, 2022
)
0.72
" Researchers assessed treatment-emergent adverse events (TEAEs) and laboratory abnormalities in patients randomized to SOF/VEL or placebo for 12 weeks in ASTRAL-1 and SOF/VEL for 12 weeks in ASTRAL-2 and ASTRAL-3."( The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
Bourgeois, S; Foster, GR; Gerken, G; Hernandez, C; Jacobson, IM; Mathurin, P; Osinusi, A; Ryder, SD; Scherbakovsky, S; Tedesco, D; Thuluvath, P; Vanstraelen, K, 2023
)
0.91
" No grade III/IV adverse events were reported, and there was no worsening of blood counts, liver or renal function test parameters."( Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
Bhagat, N; Charak, S; De, A; Duseja, A; Goel, K; Premkumar, M; Rathi, S; Sharma, A; Singh, V; Taneja, S; Verma, N, 2023
)
0.91
" Thirty-three reported adverse events (AEs) were considered related to the administration of SOF/VEL, all of them were mild or moderate."( Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study.
Aniszewska, M; Dobrzeniecka, A; Indolfi, G; Marczyńska, M; Pluta, M; Pokorska-Śpiewak, M; Talarek, E, 2023
)
0.91
" Overall, sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir were safe and well tolerated."( Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.
Ahn, SH; Byun, KS; Cho, JY; Heo, J; Jang, BK; Jang, JW; Jeong, SH; Jung, YJ; Kim, HJ; Kim, IH; Kim, JH; Kim, YJ; Kwon, JH; Kwon, KM; Lee, BS; Lee, SW; Lee, YJ; Lim, YS; Paik, SW; Park, NH; Suri, V; Tak, WY; Wu, P; Yang, SH; Yoon, KT, 2023
)
0.91
"Treatment with sofosbuvir-velpatasvir or sofosbuvir-velpatasvir-voxilaprevir was safe and resulted in high SVR12 rates in Korean HCV patients."( Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.
Ahn, SH; Byun, KS; Cho, JY; Heo, J; Jang, BK; Jang, JW; Jeong, SH; Jung, YJ; Kim, HJ; Kim, IH; Kim, JH; Kim, YJ; Kwon, JH; Kwon, KM; Lee, BS; Lee, SW; Lee, YJ; Lim, YS; Paik, SW; Park, NH; Suri, V; Tak, WY; Wu, P; Yang, SH; Yoon, KT, 2023
)
0.91
"Due to concerns over potential interactions between some hepatitis C direct-acting antivirals (DAAs) and opioids, we describe adverse event (AE) reports of concomitant use of opioids and DAAs."( Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021.
Collins, M; Conway, B; Dylla, DE; Khan, T; Marcinak, J; Martinez, A; Saget, B, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetics and safety assessments were performed, and pharmacokinetic parameters were calculated using non-compartmental methods and summarized using descriptive statistics and compared statistically by geometric least-squares mean ratios and 90% confidence intervals."( Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R, 2018
)
0.48
" Although both have been approved in China, there are currently no data on their pharmacokinetic profiles in Chinese individuals."( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020
)
0.56
" Plasma pharmacokinetic parameters were estimated by using noncompartmental models, and safety was assessed through clinical evaluation and monitoring of adverse events."( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020
)
0.56
" The pharmacokinetic parameters for sofosbuvir, GS-566500, GS-331007, and ledipasvir or velpatasvir were similar to historical values in non-Chinese subjects."( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020
)
0.56
"Overall, ledipasvir/sofosbuvir and sofosbuvir/velpatasvir exhibited pharmacokinetic and safety profiles in healthy Chinese subjects similar to those in non-Chinese subjects in historical studies, supporting their use in the Chinese population with HCV infection."( Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X, 2020
)
0.56
"This case report describes a pharmacokinetic drug-drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity."( Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report.
Batista, R; Blanchet, B; Cabanes, L; Chouchana, L; Goldwasser, F; Huillard, O; Khoudour, N; Monribot, A; Pallet, N; Préta, LH; Sogni, P; Thomas-Schoemann, A, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" The purpose of this study was to evaluate the potential of VEL as a perpetrator or victim of metabolic- and transporter-based drug-drug interactions using complementary probe drugs."( Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.
Brainard, D; German, P; Kearney, BP; Mathias, A; McNally, J; Mogalian, E; Moorehead, L; Yang, CY, 2016
)
0.43
" metabolizing enzymes on the disposition of VEL was characterized through the use of complementary probes, despite the lack of phenotypic specificity, and informs a broad range of drug-drug interaction recommendations."( Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.
Brainard, D; German, P; Kearney, BP; Mathias, A; McNally, J; Mogalian, E; Moorehead, L; Yang, CY, 2016
)
0.43
" No clinically relevant differences in the pharmacokinetics (PK) of SOF, SOF metabolite GS-331007, or VEL were observed other than an approximate 50% decrease in VEL exposure when administered with EFV/FTC/TDF."( Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
Brainard, DM; Ling, KHJ; Mathias, A; Mogalian, E; Osinusi, A; Shen, G; Stamm, LM, 2018
)
0.48
" The last wave of DAAs is also characterized by a lesser tendency to generate or being victim of drug-drug interactions."( Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy.
Cariti, G; Di Perri, G, 2019
)
0.51
"The increasing number of direct-acting antiviral (DAA) regimens along with limited number of subjects and co-medications involved in clinical trials results in drug-drug interactions (DDIs) with DAAs is to be determined."( Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.
Au, CL; Chan, HL; Hui, VW; Lai, JC; Lam, ASM; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2022
)
0.72
"This case report describes a pharmacokinetic drug-drug interaction between crizotinib, a tyrosine kinase inhibitor, and sofosbuvir/velpatasvir, a direct-acting antiviral drug, leading to cardiac toxicity."( Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report.
Batista, R; Blanchet, B; Cabanes, L; Chouchana, L; Goldwasser, F; Huillard, O; Khoudour, N; Monribot, A; Pallet, N; Préta, LH; Sogni, P; Thomas-Schoemann, A, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" In the present study, a sensitive bioanalytical method for velpatasvir was developed using high-performance liquid chromatography coupled with a fluorescence detector system, which was applied to elucidate the factors determining the oral bioavailability and disposition of velpatasvir."( A simple and sensitive HPLC-FL method for bioanalysis of velpatasvir, a novel hepatitis C virus NS5A inhibitor, in rat plasma: Investigation of factors determining its oral bioavailability.
Choi, E; Han, DG; Jung, Y; Lee, HY; Park, JE; Song, IS; Yoo, JW; Yoon, IS, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" GS-5816 5-150 mg for 3 days was well tolerated and resulted in rapid declines in HCV RNA that were sustained over the dosing period."( A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.
Brainard, DM; Freilich, B; German, P; Han, L; Lawitz, E; Link, J; Marbury, T; McNally, J; Mo, H; Rodriguez-Torres, M, 2015
)
1.59
" Geometric least squares means ratios (coadministration:alone) and 90% confidence intervals were constructed for area under the plasma concentration-time curve over the dosing interval, maximum concentration, and trough, for all analytes."( Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
Brainard, DM; Ling, KHJ; Mathias, A; Mogalian, E; Osinusi, A; Shen, G; Stamm, LM, 2018
)
0.48
" We evaluated non-adherence (<90% adherent) as measured by electronic blister-pack assessed using logistic regression and generalised estimating equations (continuous) with detailed analyses of dosing dynamics."( Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.
Amin, J; Applegate, TL; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Dunlop, AJ; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Litwin, AH; Marks, P; Matthews, GV; Norton, B; Powis, J; Quiene, S; Read, P; Shaw, D; Siriragavan, S; Thurnheer, MC; Weltman, M, 2018
)
0.48
"Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not licensed for this indication, and there is an absence of dosing recommendations in this population."( Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Agarwal, K; Ampuero, J; Ben-Ari, Z; Borgia, SM; Brown, A; Bruck, R; Calleja, JL; Cooper, C; Cramp, ME; Dearden, J; Dvory-Sobol, H; Esteban, R; Fox, R; Foxton, M; Gane, EJ; Haider, S; Hyland, R; Kirby, BJ; Lu, S; Lurie, Y; Markova, S; Meng, A; Osinusi, AO; Rodriguez, CF; Ryder, SD; Shafran, SD; Shaw, D; Willems, B; Yoshida, EM, 2019
)
0.51
" Despite the lack of dosing recommendations, sofosbuvir-containing regimens (including sofosbuvir/velpatasvir) are frequently used for HCV-infected patients undergoing dialysis."( Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Agarwal, K; Ampuero, J; Ben-Ari, Z; Borgia, SM; Brown, A; Bruck, R; Calleja, JL; Cooper, C; Cramp, ME; Dearden, J; Dvory-Sobol, H; Esteban, R; Fox, R; Foxton, M; Gane, EJ; Haider, S; Hyland, R; Kirby, BJ; Lu, S; Lurie, Y; Markova, S; Meng, A; Osinusi, AO; Rodriguez, CF; Ryder, SD; Shafran, SD; Shaw, D; Willems, B; Yoshida, EM, 2019
)
0.51
"Two chemometric assisted spectrophotometric models were applied for the quantitative analysis of velpatasvir and sofosbuvir in their newly FDA approved pharmaceutical dosage form."( Simultaneous spectrophotometric quantitative analysis of velpatasvir and sofosbuvir in recently approved FDA pharmaceutical preparation using artificial neural networks and genetic algorithm artificial neural networks.
Abdelazim, AH; Attia, KAM; El-Abasawi, NM; El-Olemy, A; Goda, AI; Shahin, M; Zeid, AM, 2021
)
0.62
"Four chemometric assisted spectrophotometric models were developed for the quantitative analysis of velpatasvir and sofosbuvir, in their newly FDA approved pharmaceutical dosage form."( Application of different chemometric assisted models for spectrophotometric quantitative analysis of velpatasvir and sofosbuvir.
Abdelazim, AH; Abu-Khadra, AS; Shahin, M, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
hepatitis C virus nonstructural protein 5A inhibitorAny inhibitor of hepatitis C virus nonstructural protein 5A.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
organic heteropentacyclic compound
N-acylpyrrolidine
L-valine derivativeA proteinogenic amino acid derivative resulting from reaction of L-valine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-valine by a heteroatom.
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nonstructural protein 5A EC50 (µMol)0.00040.00000.13758.1000AID1588160; AID1588161; AID1588164; AID1588165; AID1588166; AID1588167; AID1588168; AID1588169; AID1588170; AID1588171; AID1588172; AID1588175; AID1588179; AID1588180; AID1588181; AID1588182; AID1588183; AID1588184; AID1588185; AID1588186; AID1588187; AID1588204; AID1588205; AID1588206; AID1588207; AID1588208; AID1588209; AID1588210; AID1588211; AID1588212; AID1588213; AID1588214
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (74)

Assay IDTitleYearJournalArticle
AID1588162Fraction absorbed in dog
AID1588223Cytotoxicity against human HuH7 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1588209Inhibition of NS5A in wild type HCV genotype 2b AY232738 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588194Volume of distribution at steady state in dog at 0.25 mg/kg, iv
AID1588205Inhibition of NS5A K44R mutant in HCV genotype 2a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588221Cytotoxicity against human MT4 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1588159Clearance in monkey at 0.5 mg/kg, iv
AID1588232Selectivity index, ratio of CC50 for human MRC5 cells infected with HCV genotype 1a H77 to EC50 for NS5A in HCV genotype 1a H77 infected in human MRC5 replicon cells
AID1588160Inhibition of NS5A in wild type HCV genotype 1a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588219Cytotoxicity against human HepG2 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1588180Inhibition of NS5A Q30H mutant in HCV genotype 1a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588168Inhibition of NS5A in HCV genotype 2b MD2b-1 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588198Half life in monkey at 0.5 mg/kg, iv
AID1588208Inhibition of NS5A in wild type HCV genotype 2b MD2b-1 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588214Inhibition of NS5A in wild type HCV genotype 3a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588182Inhibition of NS5A L31M mutant in HCV genotype 1a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588201Oral bioavailability in dog at 0.5 mg/kg
AID1588179Inhibition of NS5A M28T mutant in HCV genotype 1a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588169Inhibition of NS5A in HCV genotype 3a S52 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588195Volume of distribution at steady state in monkey at 0.5 mg/kg, iv
AID1588200Oral bioavailability in rat at 2 mg/kg
AID1588164Inhibition of NS5A in HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588206Inhibition of NS5A N62V mutant in HCV genotype 2a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588185Inhibition of NS5A Y93H mutant in HCV genotype 1a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588172Inhibition of NS5A in HCV genotype 6e D88 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588202Oral bioavailability in monkey at 1 mg/kg
AID1588181Inhibition of NS5A Q30R mutant in HCV genotype 1a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588170Inhibition of NS5A in HCV genotype 4a ED43 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588161Inhibition of NS5A in HCV genotype 6a HK6 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1649896Drug excretion in human urine2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1588228Selectivity index, ratio of CC50 for human Huh7 cells infected with HCV genotype 1a H77 to EC50 for NS5A in HCV genotype 1a H77 infected in human HuH7 replicon cells
AID1588193Volume of distribution at steady state in rat at 2 mg/kg, iv
AID1588207Inhibition of NS5A N62S mutant in HCV genotype 2a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588197Half life in dog at 0.25 mg/kg, iv
AID1588211Inhibition of NS5A Y93H mutant in HCV genotype 3a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588199Half life in human at 100 mg, po
AID1588171Inhibition of NS5A in HCV genotype 5a SA13 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588163Fraction absorbed in cynomolgus monkey
AID1588189Unbound drug level in dog plasma
AID1588184Inhibition of NS5A Q30E mutant in HCV genotype 1a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588183Inhibition of NS5A Y93C mutant in HCV genotype 1a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588210Inhibition of NS5A A30K mutant in HCV genotype 3a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588203Oral bioavailability in human at 100 mg
AID1649893Half life in human2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1588229Selectivity index, ratio of CC50 for human HepG2 cells infected with HCV genotype 1a H77 to EC50 for NS5A in HCV genotype 1a H77 infected in human HepG2 replicon cells
AID1588187Inhibition of NS5A Y93H mutant in HCV genotype 1b infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588230Selectivity index, ratio of CC50 for human PC3 cells infected with HCV genotype 1a H77 to EC50 for NS5A in HCV genotype 1a H77 infected in human PC3 replicon cells
AID1588227Cytotoxicity against human MRC5 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1649892Inhibition of HCV NS3/4a protease2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1588165Inhibition of NS5A in HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588213Inhibition of NS5A P58S mutant in HCV genotype 2b infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588231Selectivity index, ratio of CC50 for human MT4 cells infected with HCV genotype 1a H77 to EC50 for NS5A in HCV genotype 1a H77 infected in human MT4 replicon cells
AID1588178Fraction absorbed in rat
AID1588186Inhibition of NS5A in wild type HCV genotype 1b infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588204Inhibition of NS5A in HCV wild type genotype 2a infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588226Cytotoxicity against human MT4 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1649895Drug excretion in human feces2019European journal of medicinal chemistry, Mar-01, Volume: 165Hepatitis C - New drugs and treatment prospects.
AID1588222Cytotoxicity against human MRC5 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1588190Unbound drug level in monkey plasma
AID1588188Unbound drug level in rat plasma
AID1588224Cytotoxicity against human HepG2 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1588212Inhibition of NS5A R44K mutant in HCV genotype 2b infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588167Inhibition of NS5A in HCV genotype 2a J6 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588220Cytotoxicity against human PC3 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1588158Clearance in dog at 0.25 mg/kg, iv
AID1588218Cytotoxicity against human HuH7 cells infected with HCV genotype 1a H77 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1588175Inhibition of NS5A L31M mutant in HCV genotype 2a J6 (M31) infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588192Clearance in rat at 2 mg/kg, iv
AID1588166Inhibition of NS5A in HCV genotype 2a JFH1 infected in human HuH7 replicon cells assessed as reduction in viral replication after 3 days by luciferase reporter gene assay
AID1588191Unbound drug level in human plasma
AID1588225Cytotoxicity against human PC3 cells infected with HCV genotype 1b Con-1 assessed as reduction in cell viability incubated for 5 days by CellTiter-Glo luminescent assay
AID1588196Half life in rat at 2 mg/kg, iv
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (219)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's118 (53.88)24.3611
2020's101 (46.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.22 (24.57)
Research Supply Index5.64 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials55 (24.34%)5.53%
Reviews27 (11.95%)6.00%
Case Studies15 (6.64%)4.05%
Observational7 (3.10%)0.25%
Other122 (53.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]